Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

Find Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Near You

Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol

Status: Recruiting
Location: See all (29) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Despite best supportive care, mortality of the Acute Respiratory Distress Syndrom (ARDS) remains high. In the absence of specific treatments, providing safe and efficient mechanical ventilation (MV) is key to survival. The use of low tidal volumes (VT) and plateau pressures (PPLAT) improves survival in randomized controlled trials (RCTs), but the safest VT to be applied for each patient remains unknown. Whether targeting low ∆P instead of a 6 mL/kg VT improves outcome has not been tested prospectively. The optimal method to set PEEP is also a matter of debate. As the amount of potentially recruitable lung vary widely among patients and is strongly associated with the response to PEEP, it may be necessary to tailor PEEP settings based on the response to a PEEP trial. The first aim is to test a personalized approach to set PEEP widely supported by the literature. The first hypothesis is that i) patients with greater amounts of recruitable lung may benefit from higher PEEP levels, provided that attention is paid to maintain ∆P below 14 cmH2O, ii) setting PEEP based on results of a PEEP-responsiveness test improves survival as compared to low- and high-PEEP strategies applied independently of the patient response. Apart from VT reduction and PPLAT control below 30 cmH2O, only 2 interventions demonstrated a reduction of mortality in large RCTs: a 48-hour continuous infusion of neuromuscular blocking agents (NMBAs) at the acute phase of ARDS6 and the use of prone positioning (PP). Whereas there is little doubt on the utility of PP in patients with PaO2/FiO2 ratio \< 150 mmHg, there is more controversy on the impact of NMBAs on survival. Despite a strong rationale and a very widespread use in clinical practice, no current guidelines answer the question of the best timing of muscle relaxation in moderate to severe ARDS patients treated with PP. As a second aim, the hypothesis is that the early systematic and combined use of NMBAs improved survival of patients with moderate to severe ARDS requiring prone positioning after optimization of PEEP settings.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Invasive mechanical ventilation within 96 hours of ICU admission and within 72 hours of tracheal intubation for first randomization and then within 72 hours of the first randomization for the second randomization

• Patients meeting the Berlin ARDS definition criteria with hypoxemia characterized as

‣ for first randomization: PaO2/FiO2 ≤150 mmHg on a PEEP ≥5 cmH2O with FiO2≥0.6 while VT is 6 ml/kg Predicted Body Weight (PBW) and adequate sedation level to adjust mechanical ventilation settings

⁃ for second randomization: PaO2/FiO2 ≤150 mmHg on optimized ventilatory settings according to the first randomization, confirmed by two Arterial blood gas (ABG) analyses separated by an interval time of 4 hours and observed within 72 hours of the first randomization

• Informed consent signed:

‣ by the patient

⁃ Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent by written as per L. 1111-6

⁃ Or in a situation urgently and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow him to consent.

• Health insurance coverage

Locations
Other Locations
France
CH Aix
RECRUITING
Aix-en-provence
Hôpital Pellegrin
RECRUITING
Bordeaux
CH Fleyriat
RECRUITING
Bourg-en-bresse
Cavale Blanche
RECRUITING
Brest
CHU de Caen Normandie
RECRUITING
Caen
Hôpital de Dieppe
RECRUITING
Dieppe
CHI Fréjus Saint Raphaël
RECRUITING
Fréjus
Hôpital Raymond Poincaré AP-HP
RECRUITING
Garches
CHU Grenoble
RECRUITING
Grenoble
CH de Bicêtre
RECRUITING
Le Kremlin-bicêtre
CH du Mans
RECRUITING
Le Mans
Croix Rousse
RECRUITING
Lyon
Groupement Hospitalier Sud
RECRUITING
Lyon
Hôpital Sait Joseph Saint Luc
RECRUITING
Lyon
APHM CHU Nord
RECRUITING
Marseille
La Timone
RECRUITING
Marseille
Hôpital de Brabois
RECRUITING
Nancy
CHU de Nantes
RECRUITING
Nantes
Hopital de l'Archet 1
RECRUITING
Nice
Hôpital Cochin AP-HP
RECRUITING
Paris
Hôpital de La Pitié Salpetrière AP-HP
RECRUITING
Paris
Hôpital Saint Louis
RECRUITING
Paris
La Pitié Salpetriere hospital - AP-HP
RECRUITING
Paris
Hôpital Charles Nicolle
RECRUITING
Rouen
Hôpital Nord
RECRUITING
Saint-etienne
CMC Foch
RECRUITING
Suresnes
Hôpital Bretonneau
RECRUITING
Tours
Centre Hospitalier de Troyes
RECRUITING
Troyes
Hôpital André Mignot
RECRUITING
Versailles
Contact Information
Primary
Alexandre Demoule, MD PhD
alexandre.demoule@aphp.fr
+33 1 42 16 38 31
Backup
Jérôme Lambert, MD PhD
jerome.lambert@u-paris.fr
+33142499742
Time Frame
Start Date: 2025-11-05
Estimated Completion Date: 2029-11-05
Participants
Target number of participants: 1200
Treatments
Active_comparator: First randomization : Arm A : Routine care Minimal distention
Decision of the ventilation strategy according to the routine care
Active_comparator: First randomization : Arm B Routine care maximal recruitment
Decision of the ventilation strategy according to the routine care
Experimental: First randomization: Arm C : Decision of th ventilation strategy according to the PRT result
Maximal recruitment strategy in patients with positive PEEP responsiveness test (PRT) or minimal distension strategy in patients with negative PRT.
Active_comparator: Second randomization : NMBAs used as a rescue
Experimental: Second randomization : early NMBAs used as soon as possible
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov